Caso contributivo
Tante visite, una diagnosi “by proxy”: ALPS, la sindrome linfoproliferativa autoimmune
Many examinations, one diagnosis by proxy: ALPS, autoimmune lymphoproliferative syndrome
L. Sirianni, M. Mancuso
UO Pediatria, Presidio Ospedaliero Soveria Mannelli, ASP Catanzaro.
Gennaio 2013
Abstract
Autoimmune lymphoproliferative syndrome or ALPS is a genetic disease associated with anomalous apoptosis in lymphocytes, lymphoproliferation and autoimmune manifestations. Generally, it is possible to observe severe lymphadenopathy, hepatosplenomegaly and autoantibodies that are often directed against erythrocytes, neutrophils and platelets. ALPS patients present with lymphocytosis and remarkable expansion in double negative T-lymphocytes (αβ+; CD4-; CD8- cells). The therapy envisages the administration of cytotoxic, glucocorticoid and antifolate drugs. In case of therapy resistance transplantation of allogenic bone marrow is feasible.
The article reports the case of a boy and his younger sister both affected by ALPS. The sister died at the age of 8 years old because of infectious pulmonary complications. The boy was diagnosed with ALPS at the age of 16 years old.
Contenuto riservato
Per leggere l'articolo è necessario effettuare il login.
Parole chiave
Suggerite dall'AI
Classificazione MeSH
Bibliografia
Canale VC, Smith CH. Chronic lymphadenopathy simulating malignant lymphoma. J Pediatr 1967;70:891-9.
2. Randall DL, Reiquam CW, Githens JH, Robinson A. Familial myeloproliferative disease. A new syndrome closely simulating myelogenous leukemia in childhood. Am J Dis Child 1965;110:479-500.
3. Siegel RM, Frederiksen JK, Zacharias DA, ChanFK, Johnson M, Lynch D, et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000;288:2354-7.
4. Puck JM, Straus SE, Le Deist F, Rieux-Laucat R, Fischer A. Inherited disorders with autoimmunity and defective lymphocyte regulation. In: OchsHD, Smith CIE, Puck JM, eds. Primary Immunodeficiency Diseases. A molecular and genetic approach. Oxford: Oxford University Press 1999: 339-52.
5. Kwon XW, Procte J, Dale JK Straus SE, Stroncek DF. Neutrophil and platelet antibodies in autoimmune lymphoproliferative syndrome. Vox Sang 2003;85:307-12.
6. Bleesing JJ, Brown MR, Straus SE, Dale JK, Siegel RM, Johnson M, et al. Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome. Blood 2001;98:2466-73.
7. Van der Werff Ten Bosch J, Schotte P, Ferster A, Azzi N, Boehler T, Laurey G, et al. Reversion of autoimmune lymphoproliferative syndrome with an antimalarial drug: preliminary results of a clinical cohort study and molecular observations. Br J Haematol 2002;117:176-88.
8. Benkerrou M, Le Deist F, de Villartay JP, Caillat-Zucman S, Rieux-Laucat F, Jabado N, et al. Correction of Fas (CD95) deficiency by haploidentical bone marrow transplantation. Eur J Immunol 1997;27:2043-47.